- Home
- Europe Prostate Cancer Diagnostics Market
Europe Prostate Cancer Diagnostics Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-105 | No of pages: 255 | Format:
Europe prostate cancer diagnostics market is projected to register a CAGR of 12.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation
Europe Prostate Cancer Diagnostics Drug Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic), Sample Type (Blood, Tissue, Urine and Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the prostate cancer diagnostics market are:
Increasing prevalence of prostate cancer.
Increased research & development in prostate cancer diagnostics.
Market Players
The key market players for the prostate cancer diagnostics market are listed below:
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Abbott
OPKO Health, Inc.
Beckman Coulter, Inc. (A Subsidiary of Danaher)
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET END USERS COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 COMPARATIVE ANALYSIS WITH PARENT MARKET
6 REGULATORY FRAMEWORK: EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
6.1 REGULATORY SCENARIO IN THE U.S.
6.2 REGULATORY SCENARIO IN EUROPEAN UNION
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF PROSTATE CANCER
7.1.2 INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
7.1.3 INCREASE IN GERIATRIC POPULATION
7.1.4 LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
7.1.5 DISEASE CAUSING PROSTATE CANCER
7.2 RESTRAINTS
7.2.1 CONTROVERSY RELATED TO PSA TESTING
7.2.2 HIGH COST OF DIAGNOSTICS PROCEDURE
7.2.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
7.3.2 REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
7.3.3 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
7.3.4 RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
7.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
7.4.3 INACCURATE DIAGNOSIS RESULTS
8 IMPACT OF COVID-19 ON EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
8.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.6 CONCLUSION
9 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 REAGENTS & CONSUMABLES
9.3 INSTRUMENTS
9.4 ACCESSORIES
10 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE
10.1 OVERVIEW
10.2 PRELIMINARY SCREENING TESTS
10.2.1 PROSTATE-SPECIFIC ANTIGEN (PSA) TEST
10.2.2 DIGITAL RECTAL EXAM (DRE) TEST
10.3 CONFIRMATORY TESTS
10.3.1 PCA3 TEST
10.3.2 BIOPSY
10.3.3 IMAGING TESTS
10.3.3.1 ULTRASOUND
10.3.3.2 MAGNETIC RESONANCE IMAGING (MRI)
10.3.3.2.1 MULTIPARAMETRIC MRI
10.3.3.2.2 MRI FUSION-GUIDED PROSTATE BIOPSY
10.3.3.3 CT SCAN
10.3.3.4 BONE SCAN
10.3.3.5 PET/CT SCAN
10.3.4 BIOMARKER
10.3.4.1 RNA BIOMARKERS
10.3.4.2 DNA BIOMARKERS
10.3.4.3 PROTEIN BIOMARKERS
11 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY TYPE
11.1 OVERVIEW
11.2 PROSTATIC ADENOCARCINOMA
11.3 SMALL CELL CARCINOMA
11.4 OTHERS
12 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
12.1 OVERVIEW
12.2 GERIATRICS
12.3 ADULT
12.4 PEDIATRIC
13 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY STAGE
13.1 OVERVIEW
13.2 LOCALIZED PROSTATE CANCER
13.3 RECURRENT/ADVANCED PROSTATE CANCER
13.4 CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
14 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 OVERVIEW
14.2 BLOOD
14.3 TISSUE
14.4 URINE
14.5 OTHERS
15 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY END USERS
15.1 OVERVIEW
15.2 INDEPENDENT DIAGNOSTIC LABORATORIES
15.3 HOSPITALS
15.4 CLINICS
15.5 AMBULATORY SURGICAL CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 SWITZERLAND
17.1.8 NETHERLANDS
17.1.9 TURKEY
17.1.10 BELGIUM
17.1.11 REST OF EUROPE
18 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLI0
20.1.5 RECENT DEVELOPMENTS
20.2 ABBOTT
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 SIEMENS HEALTHCARE GMBH
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 OPKO HEALTH INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 ACCUQUIK TEST KITS
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 ACON LABORATORIES INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENTS
20.8 BIOMERIEUX SA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 DIASORIN S.P.A
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLI0
20.9.4 RECENT DEVELOPMENTS
20.10 EUROLYSER DIAGNOSTICA GMBH
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENT
20.11 FUJIREBIO
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLI
20.11.3 RECENT DEVELOPMENTS
20.12 GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HOLOGIC, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 HUMASIS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 MDXHEALTHCARE
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 METAMARK GENETICS, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLI0
20.16.3 RECENT DEVELOPMENTS
20.17 MYRAID GENETICS, INC.
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 PROSTATYPE GENOMICS
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 PROTEOMEDIX
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.20 TECO DIAGNOSTICS
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Segmentation
Short Description
Europe Prostate Cancer Diagnostics Drug Market, By Product Type (Instruments, Reagents & Consumables and Accessories), Diagnostics Type (Preliminary Screening Tests, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Type (Prostatic Adenocarcinoma, Small Cell Carcinoma and Others), Stage (Localized Prostate Cancer, Recurrent/Advanced Prostate Cancer and Castration-Resistant Prostate Cancer (Metastatic and Non-Metastatic), Sample Type (Blood, Tissue, Urine and Others), End Users (Independent Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends and Forecast to 2028
Market Definition
The prostate cancer begins when the cells in the prostate gland started to grow at an abnormal pace and the condition is known to be prostate cancer. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. The prostate cancer diagnostics is a technique of detection of cancer mainly in the early stage to conduct the future treatment approach which can increase the survival rate. It includes in-vitro diagnosis, medical imagining among others used as the diagnostics approach for the prostate cancer detection and some advanced diagnostics method approved in the recent past. The improper or inaccurate diagnosis of prostate cancer leads to wrong treatment which cause extra burden on the patients pocket and cause decrease in reliability for the diagnostics products.
The prostate cancer diagnostics show advancement in the research & development and the approval of new product. There are certain instruments which are used for the detection of prostate cancer. The ultrasound, MRI has been proven useful for analyzing whether the cancer has spread or not. The detection of prostate cancer is quite reproducible and sensitive. Reagents are normally used to test the presence of antigens such as prostate specific antigen (PSA), the reagent binding to the related substances which trigger specific reactions.
The preliminary detection test is majorly done to find cancer at an early stage so that it wont get spread and may be at high risk for spreading if not treated. Preliminary screening involves 2 basic types of test: PSA test and DRE test. When the abnormality is founded in the preliminary test, the confirmatory test is done such as ultrasound and MRI assisted TRUS.
The demand for prostate cancer diagnostics market has been increased in both developed as well as in developing countries and the reason behind this is the increasing prevalence of prostate cancer across the globe for which the diagnostics products is used to detect the cancer type and stage. The prostate cancer diagnostics market is growing due to increase in geriatric population, launch of new products for prostate cancer diagnostics and reimbursement policy for prostate cancer diagnostics. The market will grow in the forecasted period due to exploration of emerging markets, strategic initiative to cancer research and increasing prostate cancer diagnostics products.
Market Segmentation
The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.
On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories.
On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests.
On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics.
On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others.
On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic).
On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others.
On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others.
On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales.
Market Players
The key market players for the prostate cancer diagnostics market are listed below:
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Abbott
OPKO Health, Inc.
Beckman Coulter, Inc. (A Subsidiary of Danaher)
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.